U.S. Food and Drug Administration Approves Gilenya to Treat Relapsing Multiple Sclerosis (MS) in Pediatric Patients

Published on in CHOP News

The FDA has approved its first-ever disease-modifying drug for children and adolescents with multiple sclerosis (MS). The drug, Gilyena® (fingolimod), has been shown to significantly reduce relapses and brain lesions.

"Repeated relapses are more common in young people with MS than in adults, said Dr. Brenda Banwell, Chief of the Division of Neurology at Children's Hospital of Philadelphia (CHOP), who served as co-principal investigator of the pivotal study that supported the pediatric approval. “This is heartening news for patients and their families,” she added.

Learn more about the FDA approval and the study data.

Contact: Amy Burkholder, The Children’s Hospital of Philadelphia, 267-426-6083

Smiling neurology patient

Why Choose CHOP Neurology

Learn more about our experience caring for children with complex neurological disorders and why you should consider us for your child’s care.

Toddler with book in his mouth

Your Child's Neurology Appointment

Find information about scheduling appointments and consultations with the Division of Neurology at CHOP, including what to expect during your visit.